""This is a coming-of-age for precision medicine in the field of prostate oncology," said Schaeffer, who is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. "Clinical-grade transcriptomic profiling of prostate tumors can help us gain insights into the responsiveness of a cancer to different therapies. This has a lot of potential power to enhance the precision with which we deploy a variety of treatments for prostate cancer.""
"These trials tested two widely used therapies-docetaxel, a chemotherapy drug, and abiraterone, a hormone therapy. The study also validated a previously known biomarker, called the Decipher RNA signature, as predictive of survival benefit from docetaxel in patients with metastatic prostate cancer. This means that a genomic test could help identify which patients are likely to respond well to chemotherapy, Schaeffer said"
"One of the key findings is that tumors with active androgen receptor signaling-a pathway involved in regulating male hormones-were linked to longer survival, while tumors that grow and divide rapidly were associated with poorer outcomes."
Analysis of tumor samples from over 1,500 patients enrolled in prior clinical trials identified specific genetic and protein-based signatures strongly associated with long-term survival outcomes. Trials tested docetaxel, a chemotherapy drug, and abiraterone, a hormone therapy. Tumors with active androgen receptor signaling were linked to longer survival, while rapidly proliferating tumors correlated with poorer outcomes. Validation of the Decipher RNA signature showed it predicts survival benefit from docetaxel in metastatic disease, indicating a genomic test could identify likely chemotherapy responders. Transcriptome-based classifiers were used to assess tumor suppressor PTEN status and related molecular patterns.
Read at News Center
Unable to calculate read time
Collection
[
|
...
]